EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer

Wenlong Wan, Fang Wei, Lu Yang, Xiao Yu, Ziqi Wang, Jianping Miao, Ben Zhao

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.118486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Wenlong Wan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Interleukin-17, Drug Resistance, Neoplasm, Immunotherapy. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Science and Technology of Hubei Province, Hubei Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the persistently poor five-year survival rate (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsInterleukin-17Drug Resistance, NeoplasmImmunotherapyReceptor Protein-Tyrosine KinasesProto-Oncogene ProteinsAnimalsAxl Receptor Tyrosine KinaseHumansMiceFemaleCell Line, Tumor

Stichwörter der Autor:innen

AXLBladder cancerIL-17Immunotherapy resistanceTumor microenvironment

Substanzen

Interleukin-17Axl Receptor Tyrosine KinaseReceptor Protein-Tyrosine KinasesProto-Oncogene ProteinsAXL protein, human

Autor:innen und Institutionen

  • Department of urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: miaojianping888@tjh.tjmu.edu.cn.
  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: zhaoben@tjh.tjmu.edu.cn.

Förderung

  • Department of Science and Technology of Hubei Province
  • Hubei Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Wan, W., Wei, F., Yang, L., Yu, X., Wang, Z., Miao, J., & Zhao, B. (2026). AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118486

Vancouver

Wan W, Wei F, Yang L, Yu X, Wang Z, Miao J, et al. AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118486

BibTeX
@article{Wan2026,
  author = {Wan, Wenlong and Wei, Fang and Yang, Lu and Yu, Xiao and Wang, Ziqi and Miao, Jianping and Zhao, Ben},
  title = {AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.118486}
}
Kostenlos starten →